In a 55-year-old patient with persistent heartburn despite two months of over‑the‑counter proton pump inhibitor therapy, obesity (BMI 32), and a 20‑pack‑year smoking history, what is the recommended next step?

Upper Endoscopy is Indicated

In this 55-year-old male patient with persistent heartburn despite two months of over-the-counter PPI therapy, obesity (BMI 32), and smoking history, you should proceed directly to upper endoscopy. This patient meets two distinct and compelling indications for endoscopy based on established guidelines.

Primary Indication: PPI-Refractory Symptoms

The patient has failed an adequate trial of PPI therapy. According to the American College of Physicians guidelines, upper endoscopy is indicated in patients with typical GERD symptoms that persist despite a therapeutic trial of 4 to 8 weeks of twice-daily PPI therapy 1. While this patient has been on over-the-counter (likely once-daily) PPI for two months, the more recent 2022 AGA guidelines support endoscopy when symptoms don't respond adequately to a PPI trial 2.

Important Caveat on PPI Dosing

Before proceeding to endoscopy, confirm the patient has been taking the PPI correctly (30-60 minutes before meals) and consider whether he received an adequate trial. The 2022 AGA guidelines recommend that if symptoms persist after 4-8 weeks of single-dose PPI, you should either increase to twice-daily dosing or switch to a more effective acid suppressive agent, then reassess at 4-8 weeks 2. However, given this patient's additional risk factors (discussed below), proceeding directly to endoscopy is justified rather than prolonging empirical therapy.

Secondary Indication: Barrett's Esophagus Screening

This patient also qualifies for screening endoscopy based on his demographic and risk factor profile. The ACP guidelines specifically state that upper endoscopy may be indicated in men older than 50 years with chronic GERD symptoms and additional risk factors including elevated body mass index and tobacco use to detect esophageal adenocarcinoma and Barrett's esophagus 1.

This patient has multiple high-risk features:

• Male sex (significantly higher risk than women)
• Age 55 years (>50 threshold)
• Obesity (BMI 32 kg/m²)
• 20 pack-year smoking history
• Persistent GERD symptoms (2 months documented, likely longer)

The guidelines emphasize that screening should not be done routinely in women of any age or men younger than 50 years due to very low cancer incidence 1. However, men over 50 with multiple risk factors represent the highest-yield population for detecting both Barrett's esophagus and early adenocarcinoma 1.

What the Endoscopy Should Include

When performing the endoscopy, ensure complete evaluation 2:

• Grade any erosive esophagitis using the Los Angeles classification
• Assess the diaphragmatic hiatus (Hill grade of flap valve)
• Measure axial hiatus hernia length if present
• Inspect for Barrett's esophagus with Prague classification and biopsy if present

Critical Point About Obesity

Research shows that patients with increased BMI who have PPI-refractory symptoms are more likely to have persistent abnormal acid exposure rather than functional heartburn or hypersensitive esophagus 3. This means your obese patient is more likely to have true ongoing reflux disease that may benefit from more aggressive therapy or even surgical intervention, making endoscopic evaluation particularly important.

What Happens After Endoscopy

• If Barrett's esophagus is found: No further screening endoscopy needed, but surveillance every 3-5 years is recommended 1
• If severe erosive esophagitis is found: Repeat endoscopy after 8 weeks of PPI therapy to assess healing and rule out Barrett's 1
• If endoscopy is normal: Consider prolonged wireless pH monitoring off PPI (96-hour preferred) to confirm or rule out GERD 2
• If initial screening is negative for Barrett's: No additional screening endoscopy is necessary even if symptoms continue 1

Common Pitfall to Avoid

Do not continue escalating empirical PPI therapy indefinitely without objective testing. The 2022 AGA guidelines emphasize that if PPI therapy continues in a patient with unproven GERD, you should evaluate appropriateness within 12 months and offer endoscopy with reflux monitoring to establish appropriate use of long-term PPI therapy 2. Given this patient's risk profile, waiting 12 months would be inappropriate—proceed to endoscopy now.